Shares of AbbVie Inc. ABBV rallied 1.37% to $173.70 Thursday, on what proved to be an all-around rough trading session for ...

Shares of AbbVie Inc. ABBV slid 1.47% to $171.35 Wednesday, on what proved to be an all-around positive trading session for ...

We recently published a list of 10 Best Dividend Kings Stocks to Invest in Now. In this article, we are going to take a look ...

We recently compiled a list of the Louis Navellier’s Top 15 Long-Term Stock Picks. In this article, we are going to take a ...

AbbVie Inc (NYSE:ABBV)., a leading biopharmaceutical company, stands at a critical juncture as it navigates the loss of ...

Stock analysts at Zacks Research decreased their FY2024 EPS estimates for AbbVie in a research report issued to clients and investors on Wednesday, January 15th. Zacks Research analyst S. Ganoria now ...

AbbVie Inc (ABBV) stock saw a modest uptick, ending the day at $173.7 which represents a slight increase of $2.35 or 1.37% from the prior close of $171.35. The stock opened at $171.45 and touched a ...

Shares of AbbVie Inc. (NYSE:ABBV – Get Free Report) have been assigned a consensus rating of “Moderate Buy” from the ...

AbbVie and Simcere Zaiming have announced an option-to-license agreement for the development of an investigational drug candidate, SIM0500.

Leerink Partners analyst David Risinger has reiterated their bullish stance on ABBV stock, giving a Buy rating yesterday.Stay Ahead of the ...

Abbvie Inc. and Simcere Zaiming Pharmaceutical Co. Ltd. are part of the volley of large deals accompanying the opening of the ...

Undervalued biotech company Regenxbio Inc. shows promise with cutting-edge gene therapy technology for AMD and MPS II. Click ...